TENX logo

Tenax Therapeutics Inc. (TENX)

$1.75

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on TENX

Market cap

$65491855

EPS

-1.49

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.92529

Price on TENX

Previous close

$1.78

Today's open

$1.81

Day's range

$1.73 - $1.84

52 week range

$1.31 - $19.40

Profile about TENX

CEO

Christopher T. Giordano

Employees

6

Headquarters

Chapel Hill, NC

Exchange

NASDAQ Capital Market

Shares outstanding

37423917

Issue type

Common Stock

TENX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on TENX

Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky

Tenax Therapeutics shares fell approximately 84% to 85% after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations on behalf of TENX investors who suffered losses.

news source

PRNewsWire • Aug 19, 2026

news preview

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX)

Tenax Therapeutics shares lost roughly 84% to 85% of their value after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations. Tenax Therapeutics shares lost roughly 84% to 85% of their value after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations.

news source

GlobeNewsWire • Aug 17, 2026

news preview

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $TENX--TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law.

news source

Business Wire • Aug 16, 2026

news preview

TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)

NEW YORK--(BUSINESS WIRE)--A single clinical readout drove Tenax Therapeutics (NASDAQ: TENX) shares down approximately 84% to 85% shareholder after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. If you held TENX shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The.

news source

Business Wire • Aug 14, 2026

news preview

TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics

Tenax Therapeutics stock lost approximately 84% to 85% of its value in a single trading session after the Phase 3 LEVEL topline readout. SueWallSt notifies investors of a pending investigation into on behalf of TENX investors who suffered losses.

news source

PRNewsWire • Aug 13, 2026

news preview

Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)

Tenax Therapeutics shareholders were left holding a substantially lower-valued stock after the Phase 3 LEVEL readout for TNX-103 -- and those losses may carry legal rights. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- A single disclosure erased approximately 84% to 85% of Tenax Therapeutics (NASDAQ: TENX) shareholder value when the Company announced that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints.

news source

PRNewsWire • Aug 12, 2026

news preview

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Tenax Therapeutics NASDAQ: TENX reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemodynamic findings will inform its next steps in the program.

news source

MarketBeat • Aug 11, 2026

news preview

Tenax Therapeutics' heart drug misses main goal in study, shares plunge

Tenax ​Therapeutics said on ‌Monday its experimental heart drug failed to meet the ​main goal of ​a late-stage study.

news source

Reuters • Aug 10, 2026

news preview

Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback

Tenax Therapeutics Inc. (NASDAQ:TENX) stock is trading lower on Monday after the company reported topline results from its Phase 3 LEVEL study evaluating oral levosimendan (TNX-103) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

news source

Benzinga • Aug 10, 2026

news preview

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

news source

Seeking Alpha • Aug 10, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Tenax Therapeutics Inc.

Open an M1 investment account to buy and sell Tenax Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in TENX on M1